On this page · 4 sections→
Where the EU money came from
Funding by EU programme. Amounts are Signia Therapeutics's own share of each project, not the project's full budget.
- Horizon 2020€2.4M · 2 projects
Projects
2 EU-funded projects, newest first. Signia Therapeutics led 2 of them as coordinator. Each links to the official record.
- SigniaCoordinator
An innovative drug development and repurposing platform for rapid identification and validation of antimicrobial therapeutics
Horizon 2020 · 2020–2023 · Project on CORDIS ↗
€2.4Mtheir share - SIGNIACoordinator
SIGNIA: An innovative drug discovery platform for rapid identification and validation of antimicrobial applications in available pharmaceutical resources and drugs open for repurposing.
Horizon 2020 · 2018–2018 · Project on CORDIS ↗
€50ktheir share
Fields it works in
Research fields recorded on its Horizon projects.
- antibiotic resistance
- coronaviruses
- drug discovery
- economic impact of epidemics
- employment
- influenza
- vaccines
- virology
Is this your organisation?
Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.
Claim this profile →Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.